412 related articles for article (PubMed ID: 25086037)
1. The importance of a gatekeeper residue on the aggregation of transthyretin: implications for transthyretin-related amyloidoses.
Sant'Anna R; Braga C; Varejão N; Pimenta KM; Graña-Montes R; Alves A; Cortines J; Cordeiro Y; Ventura S; Foguel D
J Biol Chem; 2014 Oct; 289(41):28324-37. PubMed ID: 25086037
[TBL] [Abstract][Full Text] [Related]
2. Uncovering the Mechanism of Aggregation of Human Transthyretin.
Saelices L; Johnson LM; Liang WY; Sawaya MR; Cascio D; Ruchala P; Whitelegge J; Jiang L; Riek R; Eisenberg DS
J Biol Chem; 2015 Nov; 290(48):28932-43. PubMed ID: 26459562
[TBL] [Abstract][Full Text] [Related]
3. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis.
Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S
FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953
[TBL] [Abstract][Full Text] [Related]
4. Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.
Si JB; Kim B; Kim JH
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922648
[TBL] [Abstract][Full Text] [Related]
5. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.
Zhao L; Buxbaum JN; Reixach N
Biochemistry; 2013 Mar; 52(11):1913-26. PubMed ID: 23414091
[TBL] [Abstract][Full Text] [Related]
6. Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.
Klimtchuk ES; Prokaeva T; Frame NM; Abdullahi HA; Spencer B; Dasari S; Cui H; Berk JL; Kurtin PJ; Connors LH; Gursky O
Proc Natl Acad Sci U S A; 2018 Jul; 115(28):E6428-E6436. PubMed ID: 29941560
[TBL] [Abstract][Full Text] [Related]
7. Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants.
Schwarzman AL; Tsiper M; Wente H; Wang A; Vitek MP; Vasiliev V; Goldgaber D
Amyloid; 2004 Mar; 11(1):1-9. PubMed ID: 15185492
[TBL] [Abstract][Full Text] [Related]
8. Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation.
Esperante SA; Varejāo N; Pinheiro F; Sant'Anna R; Luque-Ortega JR; Alfonso C; Sora V; Papaleo E; Rivas G; Reverter D; Ventura S
J Biol Chem; 2021 Sep; 297(3):101039. PubMed ID: 34343569
[TBL] [Abstract][Full Text] [Related]
9. Specific disruption of transthyretin(105-115) fibrilization using "stabilizing" inhibitors of transthyretin amyloidogenesis.
Liang Y; Ore MO; Morin S; Wilson DJ
Biochemistry; 2012 Apr; 51(16):3523-30. PubMed ID: 22482799
[TBL] [Abstract][Full Text] [Related]
10. The Regulatory Mechanism of Transthyretin Irreversible Aggregation through Liquid-to-Solid Phase Transition.
Duan G; Li Y; Ye M; Liu H; Wang N; Luo S
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835140
[TBL] [Abstract][Full Text] [Related]
11. A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis).
Gonzalez-Duarte A; Ulloa-Aguirre A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884963
[TBL] [Abstract][Full Text] [Related]
12. Amyloid formation by human carboxypeptidase D transthyretin-like domain under physiological conditions.
Garcia-Pardo J; Graña-Montes R; Fernandez-Mendez M; Ruyra A; Roher N; Aviles FX; Lorenzo J; Ventura S
J Biol Chem; 2014 Dec; 289(49):33783-96. PubMed ID: 25294878
[TBL] [Abstract][Full Text] [Related]
13. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of transthyretin aggregation and toxicity.
Gasperini RJ; Klaver DW; Hou X; Aguilar MI; Small DH
Subcell Biochem; 2012; 65():211-24. PubMed ID: 23225005
[TBL] [Abstract][Full Text] [Related]
15. Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case.
Robinson LZ; Reixach N
Biochemistry; 2014 Oct; 53(41):6496-510. PubMed ID: 25245430
[TBL] [Abstract][Full Text] [Related]
16. Amyloidogenic potential of transthyretin variants: insights from structural and computational analyses.
Cendron L; Trovato A; Seno F; Folli C; Alfieri B; Zanotti G; Berni R
J Biol Chem; 2009 Sep; 284(38):25832-41. PubMed ID: 19602727
[TBL] [Abstract][Full Text] [Related]
17. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
Rodrigues JR; Simões CJ; Silva CG; Brito RM
Protein Sci; 2010 Feb; 19(2):202-19. PubMed ID: 19937650
[TBL] [Abstract][Full Text] [Related]
18. Familial amyloidotic polyneuropathy: protein aggregation in the peripheral nervous system.
João Saraiva M; Mendes Sousa M; Cardoso I; Fernandes R
J Mol Neurosci; 2004; 23(1-2):35-40. PubMed ID: 15126690
[TBL] [Abstract][Full Text] [Related]
19. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
Lai Z; Colón W; Kelly JW
Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of the stabilities of synthetic
Raimondi S; Mangione PP; Verona G; Canetti D; Nocerino P; Marchese L; Piccarducci R; Mondani V; Faravelli G; Taylor GW; Gillmore JD; Corazza A; Pepys MB; Giorgetti S; Bellotti V
J Biol Chem; 2020 Aug; 295(33):11379-11387. PubMed ID: 32571879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]